Articles

Norfolk Southern Corp.’s decision to replace fired Chief Executive Alan Shaw with Mark George, the railroad operator’s executive vice president and chief financial officer, should bring management-level stability to the company — but questions about its board governance still linger, according to one analyst. 

Online brokerage eToro just agreed to pay $1.5 million in a lawsuit with the Securities and Exchange Commission that could affect how you trade crypto in the future.

“It is complicated to age well in America,” says Debra Whitman, executive vice president and chief public policy officer at AARP.

The 30-year mortgage rate is averaging at 6.2% Freddie Mac said in its latest weekly survey on Thursday.

GE Vernova’s stock pulled an intraday U-turn to trade at fresh highs on Thursday, after the renewable-energy company trimmed its outlook for third-quarter profitability but affirmed its full-year outlook.

Delta Air Lines expects positive unit revenue in September for both its domestic and transatlantic businesses.

Verizon Communications Inc. said Thursday it expects charges of up to $1.9 billion in its third quarter in connection with employee buyouts.

Dow Inc.’s stock fell to fresh lows for the year on Thursday, after the materials-science company issued a revenue warning, citing higher costs and a “significant” issue at an ethylene plant.

The U.S.’s largest banks will benefit in a myriad of ways from the U.S. Federal Reserve’s upcoming changes to its capital requirement proposals to bulk up balance sheets for potential systemic problems, KBW analysts David Konrad and Scott McGratty say.

The settlement resolves a lawsuit filed by the Consumer Financial Protection Bureau in 2017, which claimed the company led borrowers astray.

Hewlett Packard Enterprise announced a series of moves Thursday to raise the financing for its $14 billion acquisition of Juniper Networks Inc., including a new revolving-credit facility and a seven-part bond deal.

Gilead’s twice-yearly injection for HIV prevention cut infections by 96% in a late-stage trial, the company said Thursday, building the case for regulatory approval of the treatment.